Antibodies targeting PD-1, PD-L1 and CTLA4 have recently shown promise in the context of metastatic melanoma and cancers with mismatch repair deficiency and are now entering trials for breast cancer. Here, CTLA4 is linked to hyperinsulinemic hypoglycemia, familial, 4.